{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:09:15Z","timestamp":1791198555985,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"University of Bordeaux 1 (BQR)"},{"name":"Agence National de la Recherche","award":["ANR-08-MNPS-019-01"],"award-info":[{"award-number":["ANR-08-MNPS-019-01"]}]},{"DOI":"10.13039\/100001671","name":"Hereditary Disease Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001671","id-type":"DOI","asserted-by":"crossref"}]},{"name":"EMBO long term fellowship","award":["ALTF975-2011"],"award-info":[{"award-number":["ALTF975-2011"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.neuropharm.2014.07.021","type":"journal-article","created":{"date-parts":[[2014,8,11]],"date-time":"2014-08-11T01:31:46Z","timestamp":1407720706000},"page":"368-374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Chronic cannabinoid receptor stimulation selectively prevents motor impairments in a mouse model of Huntington's disease"],"prefix":"10.1016","volume":"89","author":[{"given":"Susanna","family":"Pietropaolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Bellocchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ruiz-Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Cabanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuowei","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Guzm\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Garret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon H.","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2014.07.021_bib1","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00008877-200409000-00005","article-title":"Windows of vulnerability to psychopathology and therapeutic strategy in the adolescent rodent model","volume":"15","author":"Adriani","year":"2004","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.07.021_bib2","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/nature02998","article-title":"Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death","volume":"431","author":"Arrasate","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2014.07.021_bib3","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.2174\/138161208785740036","article-title":"The endocannabinoid system and multiple sclerosis","volume":"14","author":"Baker","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.neuropharm.2014.07.021_bib4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/brain\/awq278","article-title":"Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease","volume":"134","author":"Blazquez","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2014.07.021_bib5","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1097\/NEN.0b013e3181ea167f","article-title":"Environmental enrichment reduces neuronal intranuclear inclusion load but has no effect on messenger RNA expression in a mouse model of Huntington disease","volume":"69","author":"Benn","year":"2010","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2014.07.021_bib6","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1073\/pnas.0511256103","article-title":"Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases","volume":"103","author":"Bodner","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2014.07.021_bib7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.brainres.2004.01.021","article-title":"Early exploratory behavior abnormalities in R6\/1 Huntington's disease transgenic mice","volume":"1005","author":"Bolivar","year":"2004","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2014.07.021_bib8","doi-asserted-by":"crossref","first-page":"18259","DOI":"10.1523\/JNEUROSCI.4008-12.2012","article-title":"Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease","volume":"32","author":"Bouchard","year":"2012","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2014.07.021_bib9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1476-5381.2010.00870.x","article-title":"Regional enhancement of cannabinoid CB1 receptor desensitization in female adolescent rats following repeated Delta-tetrahydrocannabinol exposure","volume":"161","author":"Burston","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.07.021_bib10","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.nbd.2011.12.017","article-title":"Unbalance of CB1 receptors expressed in GABAergic and glutamatergic neurons in a transgenic mouse model of Huntington's disease","volume":"45","author":"Chiodi","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2014.07.021_bib11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0306-4522(01)00409-2","article-title":"Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's disease","volume":"109","author":"Clifford","year":"2002","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2014.07.021_bib12","first-page":"219","article-title":"Behavioral changes in Huntington disease","volume":"14","author":"Craufurd","year":"2001","journal-title":"Neuropsychiatry Neuropsychol. Behav. Neurol."},{"key":"10.1016\/j.neuropharm.2014.07.021_bib13","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.neuron.2010.12.035","article-title":"Huntington's disease: can mice lead the way to treatment?","volume":"69","author":"Crook","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2014.07.021_bib14","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.neuroscience.2010.06.056","article-title":"Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice","volume":"170","author":"Dowie","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2014.07.021_bib15","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.neuroscience.2009.06.014","article-title":"Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease","volume":"163","author":"Dowie","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2014.07.021_bib16","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.biopsych.2006.11.034","article-title":"Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study","volume":"62","author":"Duff","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2014.07.021_bib17","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0306-4522(93)90352-G","article-title":"Loss of cannabinoid receptors in the substantia nigra in Huntington's disease","volume":"56","author":"Glass","year":"1993","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2014.07.021_bib18","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0306-4522(00)00008-7","article-title":"The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease","volume":"97","author":"Glass","year":"2000","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.neuropharm.2014.07.021_bib19","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0306-4522(03)00595-5","article-title":"Delayed onset of Huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors","volume":"123","author":"Glass","year":"2004","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2014.07.021_bib20","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1111\/j.1460-9568.2005.04365.x","article-title":"Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine","volume":"22","author":"Grote","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2014.07.021_bib21","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.pnpbp.2012.04.011","article-title":"Acetaminophen differentially enhances social behavior and cortical cannabinoid levels in inbred mice","volume":"38","author":"Gould","year":"2012","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2014.07.021_bib22","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1046\/j.1460-9568.2002.02192.x","article-title":"The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety","volume":"16","author":"Haller","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2014.07.021_bib23","doi-asserted-by":"crossref","first-page":"e26617","DOI":"10.1371\/journal.pone.0026617","article-title":"Circuit specific functions of cannabinoid CB1 receptor in the balance of investigatory drive and exploration","volume":"6","author":"Haring","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2014.07.021_bib24","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/nm.f.1869","article-title":"Endocannabinoid signaling as a synaptic circuit breaker in neurological disease","volume":"14","author":"Katona","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2014.07.021_bib25","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3389\/fnbeh.2011.00037","article-title":"Aav-mediated overexpression of the CB1 receptor in the mPFC of adult rats alters cognitive flexibility, social behavior, and emotional reactivity","volume":"5","author":"Klugmann","year":"2011","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2014.07.021_bib26","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/gbb.12045","article-title":"CB1 receptor signaling regulates social anxiety and memory","volume":"12","author":"Litvin","year":"2013","journal-title":"Genes. Brain Behav."},{"key":"10.1016\/j.neuropharm.2014.07.021_bib27","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.pneurobio.2006.11.006","article-title":"The endocannabinoid pathway in Huntington's disease: a comparison with other neurodegenerative diseases","volume":"81","author":"Maccarrone","year":"2007","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2014.07.021_bib28","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/3-540-26573-2_10","article-title":"Distribution of cannabinoid receptors in the central and peripheral nervous system","author":"Mackie","year":"2005","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.07.021_bib29","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2014.07.021_bib30","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1523\/JNEUROSCI.4320-04.2005","article-title":"Deficits in experience-dependent cortical plasticity and sensory-discrimination learning in presymptomatic Huntington's disease mice","volume":"25","author":"Mazarakis","year":"2005","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2014.07.021_bib31","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1111\/j.1432-1033.2004.04460.x","article-title":"Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice","volume":"271","author":"McCaw","year":"2004","journal-title":"Eur. J. Biochem"},{"key":"10.1016\/j.neuropharm.2014.07.021_bib32","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s12035-007-8008-6","article-title":"Endocannabinoids and traumatic brain injury","volume":"36","author":"Mechoulam","year":"2007","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2014.07.021_bib33","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.nbd.2011.03.006","article-title":"Worsening of Huntington disease phenotype in CB1 receptor knockout mice","volume":"42","author":"Mievis","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2014.07.021_bib34","doi-asserted-by":"crossref","first-page":"10541","DOI":"10.1523\/JNEUROSCI.0146-10.2010","article-title":"Quantitative relationships between huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide novel insight into huntington's disease molecular pathogenesis","volume":"30","author":"Miller","year":"2010","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2014.07.021_bib35","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.neuroscience.2003.08.053","article-title":"Molecular and behavioral analysis of the R6\/1 Huntington's disease transgenic mouse","volume":"122","author":"Naver","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2014.07.021_bib36","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.biopsych.2011.11.027","article-title":"beta-arrestin2 regulates cannabinoid CB1 receptor signaling and adaptation in a central nervous system region-dependent manner","volume":"71","author":"Nguyen","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2014.07.021_bib37","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1093\/brain\/awp239","article-title":"Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity","volume":"132","author":"Palazuelos","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2014.07.021_bib38","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1098\/rstb.2011.0381","article-title":"Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities","volume":"367","author":"Pertwee","year":"2012","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.neuropharm.2014.07.021_bib39","doi-asserted-by":"crossref","first-page":"e17073","DOI":"10.1371\/journal.pone.0017073","article-title":"Genetic-background modulation of core and variable autistic-like symptoms in FMR1 knock-out mice","volume":"6","author":"Pietropaolo","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2014.07.021_bib40","doi-asserted-by":"crossref","first-page":"e19965","DOI":"10.1371\/journal.pone.0019965","article-title":"Sex-dependent changes in social behaviors in motor pre-symptomatic R6\/1 mice","volume":"6","author":"Pietropaolo","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2014.07.021_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurobiolaging.2011.09.012","article-title":"Early development of social deficits in APP and APP-PS1 mice","volume":"33","author":"Pietropaolo","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2014.07.021_bib42","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1476-5381.2010.00773.x","article-title":"Neuroprotective potential of CB1 receptor agonists in an in\u00a0vitro model of Huntington's disease","volume":"160","author":"Scotter","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.07.021_bib43","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/npp.2013.81","article-title":"Phencyclidine-induced social withdrawal results from deficient stimulation of cannabinoid CB(1) receptors: implications for schizophrenia","volume":"38","author":"Seillier","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2014.07.021_bib44","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0149-7634(00)00014-2","article-title":"The adolescent brain and age-related behavioral manifestations","volume":"24","author":"Spear","year":"2000","journal-title":"Neurosci. Biobehav Rev."},{"key":"10.1016\/j.neuropharm.2014.07.021_bib45","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1523\/JNEUROSCI.1658-03.2004","article-title":"Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism","volume":"24","author":"Spires","year":"2004","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2014.07.021_bib46","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1474-4422(09)70170-X","article-title":"Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data","volume":"8","author":"Tabrizi","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2014.07.021_bib47","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1124\/jpet.108.141069","article-title":"Divergent effects of anandamide transporter inhibitors with different target selectivity on social play behavior in adolescent rats","volume":"328","author":"Trezza","year":"2009","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2014.07.021_bib48","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ejphar.2008.01.058","article-title":"Cannabis and the developing brain: insights from behavior","volume":"585","author":"Trezza","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.07.021_bib49","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/35008142","article-title":"Delaying the onset of Huntington's in mice","volume":"404","author":"van Dellen","year":"2000","journal-title":"Nature"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390814002834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390814002834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,30]],"date-time":"2018-09-30T21:53:29Z","timestamp":1538344409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390814002834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":49,"alternative-id":["S0028390814002834"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2014.07.021","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic cannabinoid receptor stimulation selectively prevents motor impairments in a mouse model of Huntington's disease","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2014.07.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}